STAT+: A new trick for old science, and biotech VCs’ scrambled playbook

URL has been copied successfully!

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

CAR-T therapies are continuing to gain traction in autoimmune disease, with a notable new case.

Also, the FDA has withdrawn approval of GSK’s leucovorin for a rare brain disorder tied to autism, closing out an unusual episode shaped in part by political pressure.

Continue to STAT+ to read the full story…

Please follow us:
Follow by Email
X (Twitter)
Whatsapp
LinkedIn
Copy link

This post was originally published here